礼来公布中和抗体联合疗法全新数据!向FDA提交紧急使用授权申请

2020-10-08 医药魔方 医药魔方

10月7日,礼来宣布了其抗SARS-CoV-2病毒中和抗体开发项目的最新进展,包括两款中和抗体 LY-CoV555与LY-CoV016(从君实引进的JS016)的联合疗法用于新确诊轻至中度COVID-

10月7日,礼来宣布了其抗SARS-CoV-2病毒中和抗体开发项目的最新进展,包括两款中和抗体 LY-CoV555与LY-CoV016(从君实引进的JS016)的联合疗法用于新确诊轻至中度COVID-19患者的BLAZE-1研究最新期中数据。

BLAZE-1研究(NCT04427501)为一项随机、双盲、安慰剂对照、II期研究,主要评估LY-CoV555和LY-CoV016相比安慰剂用于治疗伴有症状COVID-19门诊患者的疗效及安全性差异,计划入选800例症状轻至中度且药物输注前3日内SARS-CoV-2样本检测为阳性的COVID-19患者。

该研究的单药治疗队列评估LY-CoV555三个剂量 (700,2800,7000 mg)的治疗效果和安全性,联合用药组评估LY-CoV555(2800mg)+ LY-CoV016(2800mg)的治疗效果和安全性。安慰剂组患者在完成各队列研究后允许进入全部受试药组交叉用药。研究主要终点是第11天SARS-CoV-2 病毒载量较基线的变化。其他终点包括因COVID-19住院的患者比例,29天内死亡率、安全性等。

截至期中分析时,联合疗法组入组112人,安慰剂对照组入组156人。结果显示,LY-CoV555+ LY-CoV016联合疗法显着降低了第11天的病毒载量(p=0.011),达到了该研究的主要终点。联合疗法还降低了第3天(p=0.016)及第7天(p<0.001)(感染过程中较早的时间点,通常能观察到更高的病毒载量)的病毒水平。该联合疗法亦达到预设的临床终点,包括自第1至11天的症状总体评分相较于基线的时间加权平均变化。探索性分析结果显示,联合疗法组第7天病毒载量依然较高的患者比例低于安慰剂对照组(3% vs 20.8%,p<0.0001)。联合疗法组COVID-19相关住院和急诊治疗的发生率低于安慰剂对照组(0.9% vs 5.8%),风险降低84.5%。

目前在接受联合疗法的患者中未观察到推测的耐药变异。联合疗法的耐受性良好,未发生与药物有关的严重不良事件(SAEs),且治疗相关的紧急不良事件(TEAEs)与安慰剂相当。

礼来计划尽快在同行评议期刊上发表LY-CoV555单药疗法和LY-CoV555+LY-CoV016联合疗法的临床数据。

LY-CoV555是礼来与AbCellera公司合作开发的用于治疗和预防COVID-19的IgG1单克隆抗体,可以直接结合SARS-CoV-2的刺突蛋白,阻断病毒黏附和进入人宿主细胞,从而起到中和病毒的作用。LY-CoV016则是礼来从君实生物获得大中华区以外开发权益的一款重组全人源单克隆中和抗体,以高亲和力特异性结合SARS-CoV-2表面刺突蛋白受体结构域,并能有效阻断病毒与宿主细胞表面受体ACE2的结合。于IgG1抗体的Fc段引入点突变,以消除抗体依赖性增强作用(ADE)、抗体依赖性细胞介导的细胞毒性作用(ADCC)及抗体依赖性细胞吞噬作用(ADCP)等效应。

在中和抗体的生产和供应方面,对于LY-CoV555单药疗法,鉴于三种剂量LY-CoV555的临床效果相似,礼来基本确认将700mg作为临床治疗剂量,并期望在2020Q4能够供应100万剂700mg的LY-CoV555,其中10万剂在10月份保证供应。对于联合疗法,礼来期望2020Q4能够供应5万剂,之后随着产能扩大以及与Amgen在抗体生产方面建立的合作,供应量从2021Q1开始将会放大。

在未充分证明上述疗法可以作为COVID-19的具有临床意义的治疗选择前,礼来决定投入巨额资金放大抗体产能其实也承担了不小的商业风险,但这同时也是制药企业为了满足全球治疗需求而承担的一种社会责任。鉴于BLAZE-1研究中联合疗法的积极数据以及此前LY-CoV555单药治疗的数据,礼来已经与全球监管机构进行了密切沟通,并向FDA正式提出了将LY-CoV555单药疗法用于高风险的新确诊轻至中度COVID-19患者的紧急使用授权(EUA)申请。礼来计划在获得更多安全性数据和产能支持后于11月份向FDA提出 LY-CoV555+LY-CoV016联合疗法的EUA申请。礼来预计2021Q2可以获得支持其向FDA提交正式上市申请(BLA)的临床数据。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-18 小天要好好生活

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-13 1581f8c42cm

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-11 1581f8c42cm

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-09 小小车医生

    抗体疗法,看到了新希望

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-09 12038f64m02暂无昵称

    学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-09 lovetcm

    #新冠肺炎##礼来#的使用了中国#君实#的中和抗体

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1646992, encodeId=771f164699281, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80717, encryptionId=0eb280e174e, topicName=联合疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fce23370592, createdName=wincls, createdTime=Tue Dec 15 02:50:33 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892904, encodeId=547089290493, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Sun Oct 18 19:07:01 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891661, encodeId=af4a891661d1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 13 02:36:53 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891200, encodeId=81e389120014, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Sun Oct 11 08:06:52 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523311, encodeId=fb45152331111, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Sat Oct 10 13:50:33 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890746, encodeId=a651890e4660, content=抗体疗法,看到了新希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201005/1d700ea3e5d64796b793e9d314f7f99b/8df8d63541164ba594db35d1a06f45c1.jpg, createdBy=76aa2511113, createdName=小小车医生, createdTime=Fri Oct 09 10:17:01 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890696, encodeId=479c89069689, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/850075858cc4481aa22c247c691bc9b6/4a0a2f141a844cb2a0af4d9ae3c281b1.jpg, createdBy=10bd2163613, createdName=12038f64m02暂无昵称, createdTime=Fri Oct 09 08:18:54 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890673, encodeId=70ab8906e31f, content=<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>,<a href='/topic/show?id=60bfe391059' target=_blank style='color:#2F92EE;'>#礼来#</a>的使用了中国<a href='/topic/show?id=053a103902aa' target=_blank style='color:#2F92EE;'>#君实#</a>的中和抗体, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎), TopicDto(id=73910, encryptionId=60bfe391059, topicName=礼来), TopicDto(id=103902, encryptionId=053a103902aa, topicName=君实)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Oct 09 03:14:09 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890671, encodeId=15078906e176, content=早日战胜疫情, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200910/7e96bbab0c5c420e8fe7846dcdd38c29/2b6be8f4b6284022a808d4f619b7aed6.jpg, createdBy=2aaa1602125, createdName=opzoro, createdTime=Fri Oct 09 01:49:04 CST 2020, time=2020-10-09, status=1, ipAttribution=)]
    2020-10-09 opzoro

    早日战胜疫情

    0

相关资讯

万春医药First In Class新药普那布林获FDA突破性疗法认定

9月4日,万春医药(BeyondSpring)宣布其First-In-Class新药注射用普那布林浓溶液获得FDA的突破性疗法认定,用于预防化疗对非髓性恶性肿瘤诱导的中性粒细胞减少症(CIN)。

赛诺菲/再生元Dupixent获FDA突破性疗法认定

据外媒报道,昨日,美国FDA授予了赛诺菲/再生元Dupixent(dupilumab,度普利尤单抗)突破性治疗指定,用于治疗12岁及以上的嗜酸性粒细胞性食管炎(EoE)患者。此次认定基于对EoE患者进

FDA授予TK216“罕见儿科疾病称号”,用于治疗尤因肉瘤

尤因肉瘤原于骨髓内的原始细胞,美国病理学家詹姆斯·尤因(James Ewing)于1921年首先报道。

FDA批准Gavreto(pralsetinib)治疗转移性RET融合阳性非小细胞肺癌

罗氏集团成员Genentech今天宣布,美国食品药品监督管理局(FDA)已批准Gavreto™(pralsetinib)用于治疗转移性RET融合阳性非小细胞肺癌(NSCLC)患者。

FDA批准每周1次长效生长激素疗法

9月1日,FDA宣布已批准诺和诺德开发的Sogroya(somapacitan)上市,用于治疗成人生长激素缺乏症。Sogroya是FDA批准的首款长效人生长激素,成人患者仅需每周1次皮下注射给药。

亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定,治疗慢性淋巴细胞白血病

9月7日,亚盛医药宣布,FDA授予其在研原创新药Bcl-2抑制剂APG-2575孤儿药资格认定,用于治疗慢性淋巴细胞白血病(CLL)。这是APG-2575获得的第二个FDA授予的孤儿药资格认定。今年7